demonstrated that downregulation of TRIM13 in multiple myeloma (MM) reduced the cell cycle progression and proliferation of tumor cells by inhibiting the activity of the NF kappa B pathway and the 20S proteasome. Here, TRIM13 is linked to Miyoshi myopathy.